Evidence map›Paper›PMID 21412497›Full record

ReviewWorld journal of gastroenterology2011

Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010.

Chakshu Sharma, Karim M Eltawil, Paul D Renfrew, Mark J Walsh, Michele Molinari

Registry-linked trialOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01734967 (Needle-based Confocal Endomicroscopy Examination of Pancreatic Masses), which is not on this map. Cited by 108 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed, 3 pooled it
9.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01734967 nacompletednot on this mapstarted 2012, after this paper: background citation

Needle-based Confocal Endomicroscopy Examination of Pancreatic Masses

TypeinterventionalSponsorHerlev HospitalRan2012 to 2016Enrolled28ConditionsPancreatic Neoplasms, CHRONIC PANCREATITISArmsneedle based CLE, EUS-FNA
3 · Its place in the literature

Who cites it

108 citing papers in PubMed, 3 syntheses or guidelines pooled it, 211 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Meta-analysis of phase III randomized trials of molecular targeted therapies for advanced pancreatic cancer.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2012
    Pooled it
  4. Trial
  5. Efficacy of percutaneous transhepatic cholangiodrainage (PTCD) in patients with unresectable pancreatic cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Trial
  6. A pilot study of nectin-4-targeted radioligand [European journal of nuclear medicine and molecular imaging · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

48 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Chakshu SharmaDepartment of Surgery, Queen Elizabeth ІІ Health Sciences Center, Dalhousie University, Halifax, Nova Scotia B3H2Y9, Canada.
Karim M Eltawil
Paul D Renfrew
Mark J Walsh
Michele Molinari
Queen Elizabeth II Health Sciences Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several advances in genetics, diagnosis and palliation of pancreatic cancer (PC) have occurred in the last decades. A multidisciplinary approach to this disease is therefore recommended. PC is relatively common as it is the fourth leading cause of cancer related mortality. Most patients present with obstructive jaundice, epigastric or back pain, weight loss and anorexia. Despite improvements in diagnostic modalities, the majority of cases are still detected in advanced stages. The only curative treatment for PC remains surgical resection. No more than 20% of patients are candidates for surgery at the time of diagnosis and survival remains quite poor as adjuvant therapies are not very effective. A small percentage of patients with borderline non-resectable PC might benefit from neo-adjuvant chemoradiation therapy enabling them to undergo resection; however, randomized controlled studies are needed to prove the benefits of this strategy. Patients with unresectable PC benefit from palliative interventions such as biliary decompression and celiac plexus block. Further clinical trials to evaluate new chemo and radiation protocols as well as identification of genetic markers for PC are needed to improve the overall survival of patients affected by PC, as the current overall 5-year survival rate of patients affected by PC is still less than 5%. The aim of this article is to review the most recent high quality literature on this topic.

Indexed as

Biomarkers, TumorCombined Modality TherapyHumansPalliative CarePancreatic NeoplasmsRetrospective StudiesRisk FactorsBiomarkers, TumorDiagnosisEpidemiologyPalliationPancreatic cancerTherapy

Identifiers

PMID21412497
PMCPMC3051138
OpenAlexW1995075702

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.